- Home
- LBTYB vs RARE Comparison
LBTYB vs RARE Comparison
Compare LBTYB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBTYB
- RARE
- Stock Information
- Founded
- LBTYB 2004
- RARE 2010
- Country
- LBTYB Bermuda
- RARE United States
- Employees
- LBTYB N/A
- RARE N/A
- Industry
- LBTYB Cable & Other Pay Television Services
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- LBTYB Telecommunications
- RARE Health Care
- Exchange
- LBTYB Nasdaq
- RARE Nasdaq
- Market Cap
- LBTYB 4.0B
- RARE 3.2B
- IPO Year
- LBTYB N/A
- RARE 2014
- Fundamental
- Price
- LBTYB $10.50
- RARE $33.12
- Analyst Decision
- LBTYB
- RARE Strong Buy
- Analyst Count
- LBTYB 0
- RARE 15
- Target Price
- LBTYB N/A
- RARE $87.00
- AVG Volume (30 Days)
- LBTYB 213.0
- RARE 1.3M
- Earning Date
- LBTYB 01-01-0001
- RARE 11-04-2025
- Dividend Yield
- LBTYB N/A
- RARE N/A
- EPS Growth
- LBTYB N/A
- RARE N/A
- EPS
- LBTYB N/A
- RARE N/A
- Revenue
- LBTYB $4,770,600,000.00
- RARE $630,598,000.00
- Revenue This Year
- LBTYB $13.25
- RARE $19.65
- Revenue Next Year
- LBTYB $1.75
- RARE $23.65
- P/E Ratio
- LBTYB N/A
- RARE N/A
- Revenue Growth
- LBTYB 170.50
- RARE 20.63
- 52 Week Low
- LBTYB $9.15
- RARE $25.81
- 52 Week High
- LBTYB $14.91
- RARE $50.00
- Technical
- Relative Strength Index (RSI)
- LBTYB 44.02
- RARE 52.05
- Support Level
- LBTYB $10.30
- RARE $29.36
- Resistance Level
- LBTYB $12.60
- RARE $35.95
- Average True Range (ATR)
- LBTYB 0.11
- RARE 1.63
- MACD
- LBTYB -0.17
- RARE -0.15
- Stochastic Oscillator
- LBTYB 7.85
- RARE 60.24
About LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.